A. Introduction B cell lineages are influenced by antigenindependent development and by immune activation when antigens stimulate the development of both memory B and plasma cell clones. It is difficult to investigate the origin of B cell malignancies without knowing the details of these physiological events. In 1974, Salmon and Seligmann [1] suggested that the various types of B lymphoid malignancies may derive from normal cells representing different levels of maturation. In addition, the degree of differentiation which takes place within the malignant clone also seems to be variable: some malignant cells, e.g. chronic lymphocytic leukaemia (CLL), are apparently "fixed" and unable to differentiate further, while in another disease, e.g. myeloma, the lymphoid or lymphoplasmacytoid "target cells" of malignancy differentiate into plasma cells. In our study we have, therefore, decided to approach the origin of B lymphoid disorders with a simple approach by asking the following questions:
1. What are the phenotypic features of B lymphocytes as they emerge in the normal bone marrow (BM) during childhood? The main aim here has been to find an answer to the question whether B cell populations in the BM versus peripheral lymphoid organs have mutually distinctive features.
2. How do B cells develop in the normal fetus? Do B cells at different sites show distinct phenotypic features? In this part of the study samples of fetal BM, para-aortic lymph nodes and spleen have been studied.
3. Can B cell types (and the corresponding B cell malignancies) change their features when stimulated in vitro?
There have been many previous clues about the early stages of B cell differentiation both in humans and animals (reviewed in [2, 3] ). Small to medium-sized lymphoid cells with terminal transferase (TdT) enzyme activity are the likely precursors of larger pre-B cells which synthesize small amounts of cytoplasmic (Cy) fl heavy chain first, but no light chain [4, 5] . These pre-B cells, in turn, give rise to B cells with membrane IgM, but no IgD expression, and probably also to a proportion of IgM+, IgD+ B cells during the next stage of development [2, 6] . But these latter cells constitute a mixture: some of them (particularly during secondary responses) appear to return to the BM from the peripheral lymphoid organs [7] . Our aim has been to establish the reactivity of these cell types using a wide range of monoclonal antibodies (MoAb) against various non-Ig membrane antigens.in combination with the analysis of Ig isotype expression. Thus, the purpose of the study is to endow the hypothetical differentiation scheme with further discriminating reagents. Clearly, Ig isotype expression alone is not sufficient for clear discrimination; e.g. mature B cells lose IgD [6] ; IgM+,IgD-cells, without further markers, cannot be affiliated to a given (early or late) maturation stage.
B. Methods
"Double-marker" methods were used with green fluorescein (FITC)-and red rhodamine (TRITC)-labelled antibodies in various ~o~binations [4, 8] . For example, the reactivIty of MoAb was studied on TdT+ cells (labelled with rabbit anti-Td1) and fl + as well as 0+ B cells (labelled with an antiIgM. and anti-I~D antisera, heavy chain spec~fic, resrectIvely). The overall proportIOn of fl ,0-and fl +, 0+ cells was also determined in each sample. In histology the same double-immunofluorescence technique [8] and immunoperoxidase was used togeth~r with haematoxylin counterstaining on sectIOns of frozen biopsies.
~e induction of differentiation changes USIng 12-0-tetradecanoylphorbol-13-acetate (phorbol ester: TPA) was an empirical method to assess links between cells expre~sing different phenotypes. The concent~atIOn of TP A in experiments with cell hnes was 10-7 M and with leukaemic cells was l.6 X 10-8 M [9, 10] . The samples used were from normal child BM or regenerating samples taken from cessation of chemotherapy for AML or ALL. The fetal tissues were from medially ~pproved abortions. All suspensions, Inc1u~Ing samples from patients with chromc lymphocytic (CLL), hairy cell leukaemia (HCL) and blood samples from normal donors, were separated on Ficoll-Hypaque gradients. (Table 2) . Second, the antigens To 15 and RFB-4, albeit absent from the cell membrane of pre-B and IgM+, IgD-cells, can be found in the cytoplasm of the same cells. As Campana et al. [9] have recently shown, blast cells in fresh cases of common acute lymphoblastic leukaemia and permanent cell lines of non-T, non-Band pre-B type (KM3, REH and NALM-6) also show a cytoplasmic, but no membrane ex-. ' preSSIOn of Tol5 and RFB-4. The interesting additional result is that these lines start expressing membrane To15 and RFB-4 when incubated with TP A for 48-72 h. It seems therefore that not only cytoplasmic fl can change to membrane IgM during B cell development, but some other molecules also demonstrate a similar sequence of events [9] .
II. Investigations of Fetal BM
Around the 17th gestational week the BM contains large numbers (40%) oflymphoid- looking cells. Of these 15%-25% were Tdr+ and a further 5%-10% were cytoplasmic IgM+ pre-B cells; the majority of B lineage cells were membrane sIgM+, sIgD-B lymphocytes. It was confirmed in tissue section that these populations were indeed predominantly negative for To15, RFB-4 and RFB-6 antigens [13] . Thus, the BM B cells in the fetus represent "early" types of B cells, as expected on the basis of findings in the infant BM (Table 2) .
Further studies were performed to identify the T-lineage cells in the fetal BM. Two antibodies, OKTI-like (UCH-Tl) and OKTI-like (RFTl) were used, the latter in double combination with anti-IgM. T cells (T3+, Tl +) were rare (0.5%-1 %) in 17-weekold fetal BM, and these were IgM-( Table  3 ). The proportion of RFT1 +, IgM+ doublelabelled cells was very low: 0.1 %-0.9% amongst the IgM+ population (0.02% -0.15%) of all BM cells. This contrasts with the findings observed in fetal lymph nodes (see Sect. C.IV).
III. Analysis of Fetal Spleen
In the samples of fetal spleen taken at the 18th gestational week 4-5 times more B cells were found than T cells. Of all cells, 464 4%-6% were IgM+ and another 1 %-2% T3+. The T cell population was clustered around small blood vessels, and the B cells formed a loose band of cells at the edge of the splenic red pulp. No follicular dendritic reticulum cells were seen.
There were two important findings about the splenic· B cells. First, these splenic B cells have clearly shown a "peripheral B cell" phenotype: 80%-90% were IgM+, IgD+ and virtually all (> 95%) B cells clearly reacted with MoAb RFB-4, To15 and RFB-6. On the other hand, we could not observe significant numbers of IgM+, IgD-B cells. This is interesting because in the adult human (and rat) spleen a clearly visible population of IgM+, IgD-cells is present in the marginal zone [14] , but these are probably mature cells in a relatively late stage of development. Second, immunohistological techniques were used to identity B cells expressing T cell-associated markers such as Tl and only a few (1 %-2% of IgM+ cells) appeared to express the T1 antigen (Table 3 ) up to the 23rd week when more T1 +, IgM+ cells appeared [13] .
IV. Analysis of Fetal Lymph Nodes
In the earliest lymph nodes found (at 16th gestational week) T and B cell areas were Fig. 1 A, B . B lymphocytes within the primary lymphoid nodules of fetal lymph nodes (20th gestational week) show double staining for IgM (A) and the T cell-associated antigen Tl (B). These B cells are accumulating around dendritic reticulum cells [13] . The rare B cells diffusely distributed in the paracortical T area are strongly IgM+ and Tl-(arrows). This B cell population is dominant in the fetal spleen (Table 2; [13] ) not yet separated. T lymphocytes (TI +, D+) as well as the IgM+ B cells (30% of lymphocytes) were diffusely mixed. No TI +, IgM+ double-labelled cells were seen. In the lymph node samples taken at 18th week tight clusters of lymphocytes appeared accumulating 100-200 cells around follicular dendritic cells (FDR cells; identified by RFD-3 antibody) and uniformly showed a peculiar phenotype. All these cells were IgM+,IgD+ (moderately strongly), expressed BA-I positivity and reacted with RFB-4, Tol5 as well as RFB-6 (B cells of peripheral type). In addition, the B cells in the clusters were invariably TI + (moderately strongly; Fig. 1 ) but HLA-DR pOSItive and D negative. The T lymphocytes (D+, TI +,HLA-DR-, IgM-) were found in the diffuse lymphoid area and showed a much stronger TI + staining. Finally, it is important to point out that within the small B lymphoid follicles no large germinal centre blasts were seen, and the BA-l-, weak IgM+, IgD-central population seen in the germinal centres of adult lymph nodes were absent.
V. Malignant B Cells
TdT+ cells are present in large proportions amongst the lymphoid cells of fetal liver [11, 15] and fetal BM [13, 15] . These cells lack a number of other B cell markers such as Y29/55 [16] , RFB-6, or show only cytoplasmic, but no membrane expression of RFB-4 or To15. The phenotypic features of these Tdr+ cells are similar to the blast cells seen in common acute lymphoblastic (cALL) and pre-B ALL [9, 11, [15] [16] [17] .
As we recently emphasized [13] , the Tl +, IgM+, IgD+ cells with peripheral B cell features (Y29/55+, RFB-6+, RFB-4+, in the presence ofTPA also remain smooth (not shown; but see [23] ). For comparison hairy cell leukaemia is shown (c X 8000). From [10] with permission I .. To15+) which cluster around follicular dendritic reticulum cells in fetal lymph nodes (see Sect. C.IV) are very similar, by phenotypic criteria, to two B cell malignancies: centrocytic lymphoma [18] and B-type chronic lymphocytic leukaemia (B-CLL; [19) ). The further distinctive phenotypic features of these malignancies are the reactivity of TU-33 Mo-Ab with centrocytic lymphoma and that of TU-l Ab with B-CLL [18] . Indeed, the normal equivalent TI +, IgM+ cells in the primary nodules of normal fetal LN samples are also heterogeneous in respect of TU-33 and TU-I expression [13] . Thus, centrocytic lymphoma and B-CLL might originate from the TU-33 + and TU-l + B cells of primary nodules, respectively.
The exact origin of hairy cell leukaemia (BCL) is nevertheless still unknown. This disease, in its typical form, is a B cell malignancy with the following features: (a) SmIg expression and Ig gene rearrangements [20] ; (b) characteristic membrane protrusions and veils; (c) strong cytoplasmic tartrate-resistant acid phosphatase activity (TRAP; [21) ); (d) reactivity with MoAb to interleukin-2 receptor (anti-Tac; [20) ); and (e) reactivity with MoAb to SBCL3 antigen, a membrane moiety not expressed by B-CLL [22] . As the "normal equivalent" cell of BCL has so far been elusive, we have investigated whether any known malignant B cells can be transformed into BCL. The details will be published elsewhere [23] and the salient observations are as follows.
First, it has been observed that the expression of TRAP enzyme activity can be readily induced by TPA in normal tonsil B cells and their mouse rosetting subset [23] during a 72-h culture period (60% and 18% positivity, respectively). A few SBCL3-positive B cells were also generated in the same cultures (25% and 7%, respectively). Only very few Tac+ B cells were seen, however, and these were best generated in 6-or 7-day cultures stimulated by PWM (Ig+ blasts; 5% Tac+). Thus, with the possible 
• 16 cases of B-CLL and 4 cases of HCL were studied. There has been no change in the features of B-CLL and HCL cultures for 72 h without TPA (except a slight decrease in M-rbc rosetting). For further details see [23] b TPA (l2-0-tetradecanoylphorbol-13-acetate) was used for 72 hat 1.6 X 10-8 M concentration c See Fig. 2 d A MoAb from Dr. Schwarting [22] e Percentage (± standard error) of cells reacting with each marker f Numbers in parentheses refer to numbers of cases exception of membrane irregularities, the features of HCL are not fully leukaemia specific. Next, various leukaemias were "induced" by TPA. These included 16 cases of B-CLL (Tl +, sIgM+, weak), 4 cases of prolymphocytic leukaemia and "mantle zone" lymphoma (strongly Ig+ positive; TI mostly negative) and 2 cases of common ALL (Td~, sIg-).
We have reported previously that TPAinduced B-CLL cells developed membrane perturbations characteristic of hairy protrusions ( Fig. 2; [l0] ). Clearly, other "HCLassociated" features could also be observed in the majority of cases. Of 16 cases, 13 had > 50% SHCL3+ cells, and 9 showed strong Tac positivity in 64% + 21 % of activated B-CLL cells; 60%-85% of cells were TRAP+ (Table 4) . These "HCL-like" features on activated B-CLL cells were much stronger than on any of the TP A-activated normal B cell populations, including the mouse rosetting subpopulation. Similar HCL-like features (e.g. membrane irregularities and SHCL3 positivity) have not been recorded in the other leukaemias, although cases of PLL and mantle zone lymphoma did develop Tac positivity (45%-80%; results not shown, but see [23] [9, 13] in fetal bone marrow are different, by a number of criteria, from peripheral B cells [9] ; and (b) there is a dichotomy amongst the peripheral B cell populations [13] . This leads to emphasizing the existence of three major B cell types in the fetus: one in the BM, and two in the periphery (Fig. 3) . To this heterogeneity further forms (e.g. germinal centre blasts, and plasma cells) are added when the individual is exposed to extrinsic antigens during later life. This scheme is similar to those presented by Galton and MacLennan [14] and also indicated by Stein et al. [18] on the basis of lymphoma heterogeneity. Indeed, the new findings here support the existence of normal B cells (most probably virgin peripheral B lymphocytes of primary lymphoid nodules) which express some T cell-associated markers such as Tl and TU-33. These B cells are also present in adults [19] , but only in smaller numbers, perhaps because they are "diluted out" by other newly emerging cell types. The finding of IgM+, Tl + normal B cells in the primary nodules may explain two unrelated puzzling phenomena. First, certain B cell malignancies express T cell-associated features with some regularity. The Tl antigen on B-CLL, Tl plus TU-33 on centrocytic lymphoma (Kiel classification; [18] ) are the obvious examples (see Sect. C.), but T3 as well as TIl molecules were also seen in a few cases of B-CLL and B lymphomas, in spite of the fact that these showed monoclonal (x or A) light chain, IgM as well as HLA-DR [24] [25] [26] [27] . Similarly, Cawley et al. [28] have emphasized that HCL were capable of expressing T cell features (sheep erythrocyte rosetting) during certain stages of disease progression. The derepression of T cell genes may be more frequent in the recently identified TI +, IgM+ cells or their malignant counterparts than in the other B cell subsets.
At least a subgroup of HCL might also be related to the B-CLL group. This is indicated by the observations of "inducing" HCL-like features in B-CLL cells with TPA (Table 4 ). Taken at face value, these results and those described by Caligaris-Cappio [10, 23] show that TP A-induced B-CLL and HCL both have abnormal membrane characteristics in terms of "hair" formation, which is not demonstrated in the equivalent normal cells. In other respects, HCL appears to be an activated variant of B-CLL or that of a closely related cell type. An alternative explanation is that the HCLassociated markers (Tac expression, TRAP and SHCL3 positivity) are nonspecific features which appear on unrelated B cell types. Clearly, more work is needed in this area, but it is already clear that other B cell malignancies such as prolymphocytic leukaemia, mantle zone lymphoma and pre-B ALL (and the corresponding cell lines) do not develop HCL-like features when induced by TPA [23] . Thus, the CLL-HCL link has so far appeared to be a rather special one. The possibility of the CLL-HCL link is also supported by the existence ofleukaemias showing circulating HCL together with B-CLL-like histological pattern [29, 30] .
Second, it has been demonstrated in the mouse that Ly-l +, IgM+ B cells are also present and, in the NZB strain, contribute to autoantibody synthesis [31] . The observation of frequent autoantibody formation in B-CLL [32] raises the possibility that in these patients the whole TI +, IgM+ lineage is hyperactive and the monoclonal malignancy might be just one of the later, although dramatic, consequences of this dysregulation. This is an interesting possibility from the point of view of preventing a malignant disease. Similarly, further studies are necessary to investigate this B cell population in autoimmune disorders. It will be interesting to see whether the increased numbers of circulating mouse rosetting B cells in rheumatoid arthritis [33] also show the TI +, IgM+ phenotype.
